Oncimmune Germany GmbH

Oncimmune is a pioneer, a leader and an expert in early cancer detection and improved cancer outcomes. Our range of diagnostic tests assist clinicians to identify the presence of cancer on average four years before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.